Focused On-demand Library for 3-hydroxyacyl-CoA dehydrogenase type-2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q99714

UPID:
HCD2_HUMAN

ALTERNATIVE NAMES:
17-beta-estradiol 17-dehydrogenase; 2-methyl-3-hydroxybutyryl-CoA dehydrogenase; 3-alpha-(17-beta)-hydroxysteroid dehydrogenase (NAD(+)); 3-hydroxy-2-methylbutyryl-CoA dehydrogenase; 3-hydroxyacyl-CoA dehydrogenase type II; 3alpha(or 20beta)-hydroxysteroid dehydrogenase; 7-alpha-hydroxysteroid dehydrogenase; Endoplasmic reticulum-associated amyloid beta-peptide-binding protein; Mitochondrial ribonuclease P protein 2; Short chain dehydrogenase/reductase family 5C member 1; Short-chain type dehydrogenase/reductase XH98G2; Type II HADH

ALTERNATIVE UPACC:
Q99714; Q5H927; Q6IBS9; Q8TCV9; Q96HD5

BACKGROUND:
The enzyme 3-hydroxyacyl-CoA dehydrogenase type-2, also known as HSD17B10, is crucial for energy production and lipid metabolism in mitochondria. It efficiently processes medium- and short-chain fatty acids, aids in the catabolism of branched-chain amino acids, and participates in steroid hormone metabolism. Its activity towards cardiolipin suggests a protective role against oxidative damage. Furthermore, HSD17B10 is implicated in the maturation of mitochondrial tRNAs, highlighting its essential function in protein synthesis.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in HSD10 mitochondrial disease, characterized by severe metabolic and neurological symptoms, targeting HSD17B10 could offer therapeutic avenues. Understanding the role of HSD17B10 could open doors to potential therapeutic strategies for metabolic and neurodegenerative disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.